CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 04 10 2021
revised: 25 10 2021
accepted: 26 10 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 16 12 2021
Statut: ppublish

Résumé

Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score (TPS). However, the association between PD-L1 TPS and the expression of CTLA-4 in tumor-infiltrating lymphocytes is unknown. Fifty-five NSCLC patients who underwent surgery in our hospital were included in this study. We measured the proportions of CTLA-4 Statistical correlations were found neither between the proportion of CTLA-4 The proportions of CTLA-4

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score (TPS). However, the association between PD-L1 TPS and the expression of CTLA-4 in tumor-infiltrating lymphocytes is unknown.
PATIENTS AND METHODS METHODS
Fifty-five NSCLC patients who underwent surgery in our hospital were included in this study. We measured the proportions of CTLA-4
RESULTS RESULTS
Statistical correlations were found neither between the proportion of CTLA-4
CONCLUSION CONCLUSIONS
The proportions of CTLA-4

Identifiants

pubmed: 34848482
pii: 41/12/6267
doi: 10.21873/anticanres.15447
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
CTLA-4 Antigen 0
CTLA4 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6267-6272

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Satoshi Muto (S)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan smutoo@fmu.ac.jp.

Sho Inomata (S)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Hikaru Yamaguchi (H)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Hayato Mine (H)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Hironori Takagi (H)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Yuki Ozaki (Y)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Masayuki Watanabe (M)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Takuya Inoue (T)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Takumi Yamaura (T)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Mitsuro Fukuhara (M)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Naoyuki Okabe (N)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Yuki Matsumura (Y)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Takeo Hasegawa (T)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Jun Osugi (J)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Mika Hoshino (M)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Mitsunori Higuchi (M)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Yutaka Shio (Y)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Hiroyuki Suzuki (H)

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH